Alpha Tau Medical (DRTS) Liabilities and Shareholders Equity (2020 - 2026)

Alpha Tau Medical (DRTS) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $108.8 million the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 34.41% year-over-year to $108.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $430.1 million (up 21.52% YoY) and the FY2025 annual result came in at $105.7 million, up 22.56% from the prior year.
• Liabilities and Shareholders Equity improved to $108.8 million in Q1 2026 per DRTS's latest filing, from $105.7 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for DRTS reached as high as $124.0 million in Q2 2022 and fell as low as $80.9 million in Q1 2025.
• A 5-year average of $106.5 million and a median of $107.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 184.61% — and 2025, when it slipped 21.0%.
• Year by year, Liabilities and Shareholders Equity stood at $120.1 million in 2022, then declined by 10.62% to $107.4 million in 2023, then declined by 19.73% to $86.2 million in 2024, then increased by 22.56% to $105.7 million in 2025, then grew by 2.95% to $108.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $108.8 million, $105.7 million, and $104.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.